Richard A Olson, MD | |
1836 South Ave, La Crosse, WI 54601-5429 | |
(608) 782-7300 | |
Not Available |
Full Name | Richard A Olson |
---|---|
Gender | Male |
Speciality | Anesthesiology |
Location | 1836 South Ave, La Crosse, Wisconsin |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1023010378 | NPI | - | NPPES |
30628300 | Medicaid | WI |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207L00000X | Anesthesiology | 26593 (Wisconsin) | Primary |
Entity Name | Gundersen Clinic Ltd |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1851343115 PECOS PAC ID: 9638082779 Enrollment ID: O20031106000139 |
News Archive
When it comes to prostate cancer biopsies, risk and reality don't always match up, according to research published online today in the Journal of Clinical Oncology.
An international study led by researchers from Université Laval and CHU de Québec-Université Laval has identified significant vascular changes in the brains of people with Huntington's disease. This breakthrough, the details of which are published in the most recent issue of Annals of Neurology, will have significant implications for our understanding of the disease and could open the door to new therapeutic targets for treating this fatal neurodegenerative condition.
Titan Pharmaceuticals, Inc. today announced the initiation of a randomized, placebo and active controlled, multi-center Phase 3 clinical study of Probuphine in the treatment of opioid addiction. This confirmatory Phase 3 study will be conducted at approximately 23 sites in the United States and randomize approximately 250 patients into three arms: Probuphine (100 patients), Suboxone® (100 patients) and placebo (50 patients).
Genocea Biosciences, a leading vaccine discovery and development company, today announced that it has licensed an extensive patent estate from the University of Washington and the Fred Hutchinson Cancer Research Center for 25 pending and issued patents related to herpes simplex virus (HSV) type 2 antigens. The addition of these patents complements the novel antigens discovered by Genocea's unique and proprietary antigen discovery technology. The combination of Genocea's novel intellectual property with the patent estate from the University of Washington provides the Company with a broad compendium of HSV antigen patents.
Previous studies have shown that proliferation of endogenous neural precursor cells cannot alone compensate for the damage to neurons and axons. From the perspective of neural plasticity, Dr. Yun Xiang and co-workers from Sun Yat-sen University in China observed the effects of functional electrical stimulation treatment on endogenous neural precursor cell proliferation and expression of basic fibroblast growth factor and epidermal growth factor in the rat brain on the infarct side.
› Verified 4 days ago
Entity Name | Gundersen Lutheran Medical Center Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1376593442 PECOS PAC ID: 2163331414 Enrollment ID: O20130619000254 |
News Archive
When it comes to prostate cancer biopsies, risk and reality don't always match up, according to research published online today in the Journal of Clinical Oncology.
An international study led by researchers from Université Laval and CHU de Québec-Université Laval has identified significant vascular changes in the brains of people with Huntington's disease. This breakthrough, the details of which are published in the most recent issue of Annals of Neurology, will have significant implications for our understanding of the disease and could open the door to new therapeutic targets for treating this fatal neurodegenerative condition.
Titan Pharmaceuticals, Inc. today announced the initiation of a randomized, placebo and active controlled, multi-center Phase 3 clinical study of Probuphine in the treatment of opioid addiction. This confirmatory Phase 3 study will be conducted at approximately 23 sites in the United States and randomize approximately 250 patients into three arms: Probuphine (100 patients), Suboxone® (100 patients) and placebo (50 patients).
Genocea Biosciences, a leading vaccine discovery and development company, today announced that it has licensed an extensive patent estate from the University of Washington and the Fred Hutchinson Cancer Research Center for 25 pending and issued patents related to herpes simplex virus (HSV) type 2 antigens. The addition of these patents complements the novel antigens discovered by Genocea's unique and proprietary antigen discovery technology. The combination of Genocea's novel intellectual property with the patent estate from the University of Washington provides the Company with a broad compendium of HSV antigen patents.
Previous studies have shown that proliferation of endogenous neural precursor cells cannot alone compensate for the damage to neurons and axons. From the perspective of neural plasticity, Dr. Yun Xiang and co-workers from Sun Yat-sen University in China observed the effects of functional electrical stimulation treatment on endogenous neural precursor cell proliferation and expression of basic fibroblast growth factor and epidermal growth factor in the rat brain on the infarct side.
› Verified 4 days ago
Mailing Address | Practice Location Address |
---|---|
Richard A Olson, MD 1836 South Ave, La Crosse, WI 54601-5429 Ph: (608) 782-7300 | Richard A Olson, MD 1836 South Ave, La Crosse, WI 54601-5429 Ph: (608) 782-7300 |
News Archive
When it comes to prostate cancer biopsies, risk and reality don't always match up, according to research published online today in the Journal of Clinical Oncology.
An international study led by researchers from Université Laval and CHU de Québec-Université Laval has identified significant vascular changes in the brains of people with Huntington's disease. This breakthrough, the details of which are published in the most recent issue of Annals of Neurology, will have significant implications for our understanding of the disease and could open the door to new therapeutic targets for treating this fatal neurodegenerative condition.
Titan Pharmaceuticals, Inc. today announced the initiation of a randomized, placebo and active controlled, multi-center Phase 3 clinical study of Probuphine in the treatment of opioid addiction. This confirmatory Phase 3 study will be conducted at approximately 23 sites in the United States and randomize approximately 250 patients into three arms: Probuphine (100 patients), Suboxone® (100 patients) and placebo (50 patients).
Genocea Biosciences, a leading vaccine discovery and development company, today announced that it has licensed an extensive patent estate from the University of Washington and the Fred Hutchinson Cancer Research Center for 25 pending and issued patents related to herpes simplex virus (HSV) type 2 antigens. The addition of these patents complements the novel antigens discovered by Genocea's unique and proprietary antigen discovery technology. The combination of Genocea's novel intellectual property with the patent estate from the University of Washington provides the Company with a broad compendium of HSV antigen patents.
Previous studies have shown that proliferation of endogenous neural precursor cells cannot alone compensate for the damage to neurons and axons. From the perspective of neural plasticity, Dr. Yun Xiang and co-workers from Sun Yat-sen University in China observed the effects of functional electrical stimulation treatment on endogenous neural precursor cell proliferation and expression of basic fibroblast growth factor and epidermal growth factor in the rat brain on the infarct side.
› Verified 4 days ago
Jeffrey Brian Trohkimoinen, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1836 South Ave, Gundersen Clinic, Ltd., La Crosse, WI 54601 Phone: 608-775-2031 | |
Robert R Groshek, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Kaytie M Curtis, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Joon Yoon, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Dr. Laura Beth Zitelman, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Stephanie Ann Neuman, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 |